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Targeting of the mitochondrion by dinuclear
thiolato-bridged arene ruthenium complexes in
cancer cells and in the apicomplexan parasite
Neospora caninum
Afonso P. Basto,†a Nicoleta Anghel,†a Riccardo Rubbiani,†b Joachim Mu¨ller,†a
David Stibal,c Federico Giannini,d Georg Su¨ss-Fink,c Vreni Balmer,a
Gilles Gasser, *e Julien Furrer *d and Andrew Hemphill *a
A library of 18 dinuclear-thiolato bridged arene ruthenium complexes, some of which with demonstrated
activity against cancer cells, was screened for activity against a transgenic Neospora caninum strain that
constitutively expresses beta-galactosidase. Initial assessments were done at concentrations of 2500,
250, 25 and 2.5 nM, and 5 compounds were further evaluated with regard to their half maximal
proliferation-inhibiting concentration (IC50). Among those, [(Z
6-p-MeC6H4Pr
i)2Ru2(m2-SC6H4-p-CH3)3]Cl
(1), [(Z6-p-MeC6H4Pr
i)2Ru2(m2-SC6H4-p-Bu
t)3]Cl (2) and [(Z
6-p-MeC6H4Pr
i)2Ru2(m2-SCH2C6H4-p-Bu
t)2-
(m2-SC6H4-p-OH)]BF4 (9) inhibited N. caninum proliferation with low C50 values of 15, 5 and 1 nM,
respectively, while [(Z6-p-MeC6H4Pr
i)2Ru2(m2-SC6H4-p-OH)3]Cl (3) and [(Z
6-p-MeC6H4Pr
i)2Ru2-
(m2-SC6H4-p-mco)3]Cl (5, mco = 4-methylcoumarinyl) were less active (IC50 = 280 and 108 nM,
respectively). These compounds did not aﬀect human foreskin fibroblast (HFF) host cells at dosages of
5 mM and above, but impaired proliferation of the human ovarian carcinoma cell line A2780 (IC50 values
of 130 nM (1), 30 nM (2), 530 nM (3), 7730 nM (5), 130 nM (9)). A2780 cancer cells were treated with
complexes 1, 2, and 5, and biodistribution analysis using inductively coupled plasma mass spectrometry
(ICP-MS) showed that most of the drugs accumulated in the mitochondrial fractions. Transmission
electron microscopy showed that the parasite mitochondrion is the primary target also in N. caninum
tachyzoites, but these compounds, when applied at 200 nM for 15 days in vitro, did not act parasiticidal.
Complexes 1, 2 and 9 applied orally at 2 and 10 mg kg1 day1 during 5 days in a neosporosis mouse
model did not reduce parasite load and did not limit parasite dissemination to the central nervous
system. In accordance with these results, ICP-MS carried out on diﬀerent organs of mice orally
administrated with complexes 1 and 9, demonstrated that the drugs were readily absorbed, and after
3 and 48 h, were mainly detected in liver and kidney, but were largely absent from the brain. Thus,
dinuclear thiolato-bridged arene ruthenium complexes exhibit interesting activities against N. caninum
in vitro, but further modifications of these promising molecules are required to improve their bioavailability
and pharmacokinetic properties in order to exert a pronounced and selective eﬀect against N. caninum
in vivo.
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Significance to metallomics
Ruthenium(II) complexes have attracted attention because of their favorable antiparasitic properties. Many diﬀerent structural scaﬀolds are being investigated
but their mode of action and targets remain largely unknown. Here, we report on the antiparasitic properties of dinuclear-thiolato bridged arene ruthenium
complexes against N. caninum. We show that their activity and uptake can be correlated with their lipophilicity and we demonstrate their ability to selectively
target the mitochondria of the parasite. In vivo experiments also reveal that the compounds accumulated in liver and kidneys, but were absent from the brain.
However, the compounds did not act as parasiticidal.
Introduction
Cancer cells and apicomplexan parasites such as Neospora
caninum and Toxoplasma gondii share a number of distinct
biological features.1 They both live and multiply within a host
organism, and they do not immediately kill their hosts, but
rather scavenge metabolites and nutrients to satisfy their own
needs.2,3 Intracellular apicomplexans have evolved distinct
mechanisms to interfere with the cell death machinery of their
host cell, by aﬀecting distinct signalling pathways.4 Similar to
the rapidly replicating stages (tachyzoites) of these apicomplexans,
cancer cells exhibit a seemingly unlimited proliferative potential.
Tissue cyst-forming stages of these parasites (bradyzoites) and
benign tumours survive within their hosts for extended periods
of time, mostly without causing extensive pathology, and they
achieve this goal by (i) disseminating into immune compromised
tissues and (ii) exhibiting immunomodulatory properties that skew
host immunity to their own favour.5
In contrast to the research on novel anti-cancer compounds,
drug discovery in parasitology is a neglected field.6 While novel
drugs have been developed against the classical neglected diseases
such asmalaria,7 trypanosomiasis8–10 and leishmaniasis,11,12 novel
options for the treatment of protozoan diseases that affect farm
animals are largely missing.13 Due to the intrinsic similarities
between parasites and cancer cells, a reasonable starting point for
the discovery of novel anti-parasitic drug candidates is to examine
compounds that are being developed against cancer. While metal-
based drugs are well-established as anti-cancer agents,14,15 the
currently used drugs against protozoan parasites are organic
compounds, and do not contain any metal atoms. However, based
on different kinetic, geometric and electronic properties, metal
complexes and organometallic complexes in particular can
undergo reactions that are different from organic agents that
could be used against parasites,16–18 as exemplified by the anti-
malarial drug candidate Ferroquine.19 The application of platinum
anti-tumour agents clearly demonstrates that metal agents can be
developed into drugs with a high impact in therapy.20 Potentially,
the same could be done for targeting protozoan parasites.
Dinuclear thiolato-bridged arene ruthenium complexes
[(Z6-p-MeC6H4Pr
i)2Ru2(m2-SR)3]
+ and [(Z6-p-MeC6H4Pr
i)2Ru2(m2-SR
1)-
(m2-SR
2)2]
+ were shown to exhibit high toxicity against several types
of cancer cells in vitro (IC50 values as low as 30 nM).
21–25 In vivo, one
of these complexes, [(Z6-p-MeC6H4Pr
i)2Ru2(m2-SC6H4-p-Bu
t)3]Cl
(2, DiRu-1), prolonged significantly the survival rate of mice
experimentally inoculated with tumour cells.26,27 Some other
mononuclear ruthenium complexes were shown to exhibit promis-
ing in vitro activities against T. gondii and N. caninum,28,29 and
we have recently reported on the activity of a panel of dinuclear
thiolato-bridged arene ruthenium complexes against T. gondii
tachyzoites.30 Some of these compounds efficiently inhibited host
cell invasion, and had an IC50 in the low nanomolar range, low
host cell toxicity, and exposure of parasites to these compounds
led to distinct alterations in the parasite mitochondrion.30
Neospora caninum is an apicomplexan, which belongs to the
family Sarcocystidae. The parasite is distributed worldwide and
infects a broad range of animals including cattle, sheep, goats,
deer, horses and dogs.31 Neospora caninum is the causative
agent of neosporosis, a serious disease associated with abortion,
stillbirth and maternal infertility in cattle and neurological dis-
orders in dogs. Dogs and other canids represent the definitive
hosts of N. caninum, where sexual development takes place. Due to
its close resemblance to T. gondii, which is of high medial as well
as veterinary medical importance, N. caninum was recurrently
misdiagnosed as such until Dubey and colleagues succeeded in
isolating the parasite in the late 1980ies.32 In contrast to T. gondii,
N. caninum has never been shown to be transmitted from animals
to humans.31 The prevalence of N. caninum varies considerably
in diﬀerent regions, however, the annual economic impact of
neosporosis, based on data of 10 countries, was calculated to be
around 1.28 billion US dollars.33
Vaccination and chemotherapy have been identified as
economically promising options for control of neosporosis,
provided suitable targets and eﬀective reagents can be made
available.34,35 Although considerable eﬀorts have been undertaken
to develop vaccines,31,36 success with recombinant vaccines has been
limited,37–39 and only live vaccines using attenuated N. caninum
strains have shown promising efficacy so far.40 As an alternative
approach, treatment with anti-parasitic drugs could be envisaged,
carried out either during pregnancy or right after birth, with the
goal to eliminate the parasite before it can cause extensive
damage to the next generation.
We here comparatively assessed the eﬀects of a series of
18 thiolato-bridged dinuclear arene ruthenium complexes,
consisting of 7 cationic trithiolato complexes [(Z6-p-MeC6H4Pr
i)2-
Ru2(m2-SC6H4-R)3]Cl (1–7), 6 cationic mixed trithiolato complexes
[(Z6-p-MeC6H4Pr
i)2Ru2(m2-SCH2C6H4-R)2(m2-SC6H4-R)]BF4 (8–13), 4
neutral dithiolato complexes [(Z6-p-MeC6H4Pr
i)2Ru2(m2-SCH2C6H4-
p-R)2Cl2] (14–17), and one neutral monothiolato complex [(Z
6-p-
MeC6H4Pr
i)2Ru2Cl2(m-Cl)(m2-SCH2C6H4-p-NO2)] (18) in the human
ovarian cancer cell line A2780 and in tachyzoites of the intra-
cellular apicomplexan N. caninum in vitro, and confirm that the
mitochondrion is the primary target in both. In addition, we report
on the limited efficacy of [(Z6-p-MeC6H4Pr
i)2Ru2(m2-SC6H4-p-
CH3)3]Cl (1), [(Z
6-p-MeC6H4Pr
i)2Ru2(m2-SC6H4-p-Bu
t)3]Cl (2)
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and [(Z6-p-MeC6H4Pr
i)2Ru2(m2-SCH2C6H4-p-Bu
t)2(m2-SC6H4-p-
OH)]BF4 (9) in an experimental neosporosis mouse model,
and studied the biodistribution of complex 1 in different
organs of mice.
Materials and methods
Chemicals and synthesis of ruthenium complexes.
All reagents for chemical synthesis were commercially available
and were used as received. Complexes 1–18 and their in vitro
efficacy against T. gondii tachyzoites were previously reported.30
All complexes were isolated as chloride or tetrafluoroborate
salts, were stable orange to red solids, and were dried in vacuum.
The analytical data matched those previously reported in the
literature.21–23,41
Culture of mammalian cells and parasite cultures
If not stated otherwise, all tissue culture media were purchased
from Gibco-BRL (Zurich, Switzerland), and biochemical reagents
were from Sigma (St. Louis, MO). Human foreskin fibroblasts
(HFF) and Vero cells (green monkey kidney epithelial cells) were
maintained in RPMI-medium containing 10% fetal calf serum
(FCS) (Gibco-BRL, Zu¨rich, Switzerland) and antibiotics as described
earlier.37 The human ovarian carcinoma A2780 cell line was
cultured in RPMI 1640 medium (Gibco) supplemented with 10%
FCS, 100 UmL1 penicillin, 100 mgmL1 streptomycin at 37 1C and
6%CO2.N. caninum beta-gal (transgenicN. caninumNc-1) expressing
the beta-galactosidase gene from E. coli,42 and theN. caninum Spain7
isolate (Nc-Spain7) were maintained in Vero cells, and were isolated
and separated from their host cells as described.43
In vitro assessment of drug eﬃcacy against N. caninum
tachyzoites
To study the eﬀects of compounds against N. caninum-beta-Gal
tachyzoites in vitro, 0.5 mM stock solutions of the complexes
were prepared in water, sterile filtered, and stored at 4 1C. The
stability of the complexes in water solutions and in mixtures
water/DMSO has been previously established.24,44,45 Drug
assays were performed using HFF as host cells.29 In short,
5 103 HFF per well were grown to confluence in a 96 well plate
in phenol-red free culture medium at 37 1C with 5% CO2.
Cultures were infected with freshly isolated N. caninum beta-gal
tachyzoites (1  103 per well) and drugs were added at the time
point of infection. Initial assessments were done by exposing
parasite cultures to 2500 nM, 250 nM, 25 nM or 2.5 nM of
each compound for a period of three days, or water was added
as a control. For IC50 determinations, 5 selected complexes
(1–3, 5 and 9; see Table 1) were added at concentrations ranging
between 0 and 2000 nM. After three days at 37 1C/5% CO2,
plates were centrifuged at 500  g, medium was removed, and
cell cultures were exposed to PBS containing 0.05% Triton-X-100.
After addition of 10 mL of 5 mM chlorophenol red-b-D-galacto-
pyranoside (CPRG; Roche Diagnostics, Rotkreuz, Switzerland)
dissolved in PBS, the absorption shift was measured at 570 nm
wavelength at various time points on a VersaMax multiplate
reader (Bucher Biotec, Basel, Switzerland). The activity, measured
as the release of chlorophenol red over time, was proportional to
the number of live parasites down to 50 per well as determined
in pilot assays. IC50 values were calculated after the logit-log-
transformation of relative growth and subsequent regression
analysis by the corresponding software tool contained in the
Excel software package (Microsoft, Seattle, WA).
For long term treatment assays, N. caninum infected HFF
grown in T25 culture flasks were exposed to 250 nM of com-
plexes 1, 2 or 9 for a period of 15 days, with medium changes
and addition of fresh compounds every 3 days. At the end, the
cultures were washed with medium and were further main-
tained in medium devoid of drugs. Regrowth of parasites was
monitored on a daily basis by light microscopy.
Measurements of cytotoxicity
Cytotoxicity assays on non-infected confluent HFF were performed
by Alamarblue assay as previously described.30 The assessments
of selected compounds on A2780 cells have been described
earlier.21–23,41
Transmission electron microscopy (TEM)
HFF (5 104 per inoculum) cultured in T25 tissue culture flasks
for 24 h were infected with 105 N. caninum beta-gal tachyzoites,
and 200 nM of complexes 1, 2 or 9 were added at 24 h post-
infection. After 6, 24 and 48 h, cells were harvested using a cell
scraper, and they were placed into the primary fixation solution
(2.5% glutaraldehyde in 100 mM sodium cacodylate buﬀer pH 7.3)
for 2 h. Specimens were then washed 2 times in cacodylate buﬀer
and were post-fixed in 2% OsO4 in cacodylate buﬀer for 2 h,
followed by washing in water, pre-staining in saturated uranyle
acetate solution, and step wise dehydration in ethanol. They
were then embedded in Epon 812-resin, and processed for
Table 1 logP values, Hammett constants sP, and eﬃcacies of dinuclear thiolato-bridged arene ruthenium complexes against N. caninum tachyzoites,
and for comparative purposes, of T. gondii tachyzoites, human foreskin fibroblasts (HFF) and the human ovarian carcinoma cell line A2780
Complexa N. caninum beta-gal IC50 (nM) T. gondii beta-gal IC50
b (nM) HFF IC50
b (mM) A2780 IC50
c (nM) logP (RSH)c sP(R)
c,d
1 15  1 34  4 800 130  10 2.98  0.28 0.17
2 5  1 62  10 41000 30  10 4.21  0.29 0.20
3 280  50 540  60 ND 530  20 1.68  0.29 0.37
5 108  19 120  20 ND 7730  1500 2.83  0.42 ND
9 1  0.3 1.2  0.5 5 130  3 3.51  0.32 0.20; 0.37
a Chloride salts of complexes 1–3 and 5 or tetrafluoroborate salts of complex 9 were used for all experiments. b Data from ref. 30. c Data from
ref. 21–23. d For complex 9, two Hammett constants sP are given, one for each group R
1 and R2.
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TEM as described.30,46 Specimens were viewed on a Phillips
CM12 transmission electron microscope operating at 60 kV.
Studies on drug uptake in human carcinoma A2780 cells
A2780 cells were maintained in RPMI 1640 medium (Gibco)
supplemented with 10% fetal calf serum (FCS, Gibco) 100 U mL1
penicillin, 100 mg mL1 streptomycin at 37 1C and 6% CO2. Seven
days prior to treatments, 1  106 cells were seeded in 175 cm2 cell
culture flask and grown until 80% of confluency, and were
incubated with the target complexes (previously dissolved in
0.1% DMSO at a concentration of 1.0 mM for 4 h). Working
concentration and incubation time were chosen in order to avoid
extended cell mass lost due to the high cytotoxicity of the
complexes and Ru amount that could aﬀord a significant deter-
mination. After this, the cultures were washed in PBS, trypsinized,
and after centrifugation (500 g for 5min at 4 1C) and re-suspension
in PBS, the pellet was collected. Mitochondria were isolated using
a mitochondria isolation kit (Cat. Nr.: MITISO2, Sigma Aldrich)
following the producer’s instructions. Briefly, the collected pellets
were re-dissolved in 1.5 mL of extraction buﬀer (delivered with the
kit) and were incubated for 15 min on ice. The samples were
homogenized with a pre-chilled dounce homogenizer (7 mL, tight
pestle A, 30 strokes) and centrifuged at 600g for 10min at 4 1C. The
supernatant was transferred in a fresh tube and centrifuged at
11000g for 10 min at 4 1C. The obtained pellets represented
mitochondrial fractions. Nuclei of A2780 cells were obtained
following an established procedure with minor modifications.47
All the fractions were isolated from the same cellular sample as the
mitochondrial fraction for direct comparative purposes. After
homogenization, the pellet obtained was redissolved in 2 mL of
a sucrose solution (0.25 M sucrose, 10 mM MgCl2) and layered
with 2mL of a second hypertonic sucrose solution (0.35M sucrose,
0.5 mMMgCl2). The suspension was centrifuged at 1450g and 4 1C
for 5 min. The pellet was re-suspended in 3 mL of the second
sucrose solution and centrifuged at 1450g and 4 1C for 5 min to
obtain the pure nuclear extract. All the steps of the isolation
procedure were monitored by phase contrast microscopy. The
supernatant phases discarded during the isolation of nuclei
and mitochondria procedures were collected and formed the
‘‘residual’’ fraction. An aliquot of crude lysate supernatant,
nuclear, mitochondrial and residual fraction was each used
for protein quantification using the Bradford method.48 The
isolated samples were then lyophilized on an Alpha 2–4 LD plus
(CHRIST) and stored at 4 1C. The distribution of ruthenium
in different subcellular fractions was quantified by inductively
coupled plasma mass spectrometry (ICP-MS) as described below.
Inductively coupled plasma mass spectrometry (ICP-MS)
ICP-MS measurements were performed on an Agilent QQQ
8800 Triple quad ICP-MS spectrometer (Agilent Technologies)
with an ASX200 autosampler (Agilent Technologies), equipped
with standard nickel cones and a ‘‘micro-mist’’ quartz nebulizer
fed with 0.3 mL min1 analytic flow (as a 2% HNO3 aqueous
solution). Ruthenium was measured against a Ru single element
standard (Merck 170347) and verified by a control (Agilent5188-
6524 PA Tuning 2). Ruthenium content of the samples was
determined by means of a 7-step serial dilution in the range
between 0 and 100 ppb in Ru (R 4 0.99) with a background
equivalent concentration of BEC: 3.3 ppt and a detection limit of
DL: 5.4 ppt. The isotope Ru99 (12.76% abundance) 101Ru (17.06%
abundance) was evaluated in ‘‘no-gas’’ mode and He-gas mode.
Spiking the samples with 1% methanol (to account for eventual
carbon content from the biological samples) resulted in equivalent
values within error ranges. A solution of Indium (500 ppb) and
Tungsten (500 ppb) was used as internal standard. The results are
expressed as ng Ru per mg protein (correction due to the diﬀerent
mass of the observed cellular compartments or organs), as mean
standard deviation error of diﬀerent independent experiments.
Treatment of N. caninum-infected mice with complexes
1, 2 and 9
Infection and treatment experiments were approved by the
Animal Welfare Committee of the Canton of Bern under the
license BE115/14. All animals were handled in strict accordance
with practices made to minimize suﬀering. Balb/c mice each,
which were purchased from Charles River Laboratories
(Sulzfeld, Germany) and maintained under conventional day/night
cycle housing conditions with water and food ad libitum. The mice
were used for the experiment after two weeks of acclimatization.
Mice were separated into experimental groups of 6 mice each, and
were infected subcutaneously with 105 cell culture-derived tachy-
zoites of the Nc-Spain7 strain.43 Prior to the start of treatments,
complexes were emulsified in corn oil by vortexing and ultrasound
bath at 37 1C. At 48 h post infection, treatments were initiated. For
each compound, one group received 2 mg of complexes 1, 2 or 9
per kg bodyweight per day for 5 consecutive days, the other group
was given 10 mg of complexes 1, 2 or 9 per kg bodyweight per day,
and a third group received corn oil only (placebo). All treatments
were applied in 100 mL by oral gavage. Following infection, all mice
were closely monitored for clinical signs by using a standardized
score sheet. Mice were inspected daily with regard to their coat
condition (ruﬄed coat = score 1; starry stiﬀ coat = score 2), weight
loss (10% loss = score 1; 15–20% weight loss = score 4), and
behaviour (hunched appearance, walking in circles, head tilt,
apathy and ataxia, all = score 1). Animals were euthanized when
the score exceeded 3 points. The experiment was terminated
latest at 21 days post-infection. Lungs and brain were collected
to determine parasite loads by real-time PCR as previously
described,43 and cerebral and lung parasite burdens were
compared between groups by the non-parametric Kruskal–
Wallis test.
Uptake and biodistribution of complex 1 in mice
Complex 1 was emulsified in corn oil by vortexing and ultra-
sound bath at 37 1C. Six Balb/c mice received the drug by oral
gavage of 100 mL at a dose of 10 mg kg1 of body weight and two
control mice received corn oil only. One control and three treated
mice were euthanized at 3 h and at 48 h post-administration. Whole
blood, liver, kidney, lungs and brain were collected, lyophilized and
the weights of the lyophilized samples were determined. The
distribution of ruthenium in the diﬀerent organs was quantified
by ICP-MS as described above.
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Results
In vitro activities of arene ruthenium complexes against
N. caninum tachyzoites
A set of 18 ruthenium complexes (see Fig. 1) were screened for
their potential to inhibit N. caninum tachyzoite proliferation in
HFF monolayers. The symmetrical Ru(II) trithiolato complexes
[(Z6-p-MeC6H4Pr
i)2Ru2(m2-SC6H4-p-CH3)3]Cl (1), [(Z
6-p-MeC6H4Pr
i)2-
Ru2(m2-SC6H4-p-Bu
t)3]Cl (2), [(Z
6-p-MeC6H4Pr
i)2Ru2(m2-SC6H4-p-
OH)3]Cl (3) and [(Z
6-p-MeC6H4Pr
i)2Ru2(m2-SC6H4-p-mco)3]Cl
(5, mco = 4-methylcoumarinyl), bearing one type of thiol
ligand21,23 and the ‘‘mixed’’ Ru(II) trithiolato complex [(Z6-p-
MeC6H4Pr
i)2Ru2(m2-SCH2C6H4-p-Bu
t)2(m2-SC6H4-p-OH)]BF4 (9),
bearing two diﬀerent thiol ligands22 inhibited the proliferation
of N. caninum tachyzoites in vitro with IC50 values between 1 and
280 nM, complex 9 being the most eﬃcient (1  0.3 nM) and
complex 3 (280  50 nM) the least active (Table 1). The
trithiolato complexes 4, 6 and 7, the mixed complexes 8 and
10–13, the dithiolato complexes 14–17, and the monothiolato
complex 18 had no measurable anti-parasitic activity or were
toxic for HFF already at concentrations of 250 nM or 2500 nM.
Overall, these compounds exhibited similar activities against
N. caninum as for T. gondii tachyzoites, with the exception of
complex 2, which was 10 times more active against N. caninum
than against T. gondii (Table 1). The activity of the compounds
against N. caninum parallels to a certain extent the results
previously found against several cancer cell lines: the IC50
values of 7 were two orders of magnitude larger than that of
the other complexes, and the mono- and dithiolato complexes
were found to be only moderately cytotoxic against cancer cell
lines (IC50 values between 0.2 and 2.5 mM).
In contrast, HFF used here as host cells for intracellular
proliferation of N. caninum tachyzoites, appeared largely unaf-
fected at several thousand-fold higher concentrations [selective
toxicity index:450 000 for complex 1,4160 000 for complex 2,
and45000 for complex 9 (Table 1)]. These compounds did not
act parasiticidal: long-term drug treatments of infected HFF
with complexes 1, 2 and 9 at 250 nM during a period of up to
15 days did not eliminate all parasites in a culture, since
regrowth of tachyzoites was observed 5–10 days after releasing
drug pressure in all three instances.
Inductively coupled plasma mass spectrometry (ICP-MS) shows
that ruthenium complexes target the mitochondrion in A2780
cancer cells
The presence of the non-physiological metal ruthenium in
dinuclear thiolato-bridged arene ruthenium complexes allows
for the use of ICP-MS to detect and quantify the uptake of the
drug candidates into cells and diﬀerent subcellular fractions.49,50
Complexes 1, 2 and 5 were chosen for these studies, 1 and 2 being
active and selective, and complex 5 representing a less active
compound. Subcellular fractionation was carried out using treated
A2780 cancer cells. Strikingly, already after a relative short incubation
time of 4 h, the large majority of the ruthenium taken up by these
cells was found to accumulate in the mitochondrial fraction (ca. 90,
97 and 71% for complexes 1, 2 and 5, respectively) (see Fig. 2).
Also, the total values for ruthenium were much higher in fractions
originating from complex 2 treated cells compared to the others,
indicating that complex 2 is taken up much more eﬃciently, which
perfectly parallels with the respective lipophilicity of the three
complexes (Table 1 & Fig. 2).
Transmission electron microscopy (TEM) identifies the
mitochondrion as the primary target of ruthenium complexes
in N. caninum tachyzoites
Due to the lack of reliable subcellular fractionation procedures
for N. caninum, the eﬀects of ruthenium complexes in this parasite
were studied by TEM (Fig. 3 and 4). In cultures maintained in the
absence of ruthenium complexes, tachyzoites were located intra-
cellularly and proliferated within a parasitophorous vacuole (PV),
surrounded by a distinct PV membrane. Tachyzoites exhibited
their typical structural features such as rhoptries, dense granules
and micronemes, and the parasite mitochondria filled with a
structured electron dense matrix and cristae could be readily
identified (Fig. 3A and B). In drug-treated cultures, changes evolved
rapidly, and were most pronounced within the mitochondrial
matrix, which appeared less electron dense in some parasites
already after 6 h of treatment with complexes 1 and 2 (Fig. 3C
and D) and also complex 9 (Fig. 4A). The other organelles appeared
non-aﬀected. After 24 h, as exemplified here for complex 9, the
changes became more evident, and the mitochondrion with its
characteristic cristae and electron dense matrix was replaced by
large vacuoles, which were either seemingly empty (Fig. 4B), or
filled with tightly spaced membrane stacks resembling autophago-
somes (Fig. 4C). However, the outer membrane of the mitochondria
was still intact, and parasites maintained their overall shape and
structural features. From 72 h onwards (Fig. 4D), the majority of
parasitophorous vacuoles contained largely lysed or distorted
parasites, with only few of the typical organelles still recogniz-
able (Fig. 4D). These changes were similar upon treatments
with all three complexes 1, 2 and 9. However, the host cell
mitochondria were still structurally intact and associated with
the PV membrane (Fig. 4D).
Eﬀects of ruthenium complexes 1, 2 and 9 in the neosporosis
mouse model
For assessment of in vivo anti-parasitic eﬀects of these ruthenium
complexes, initial studies were carried out on complexes 1 and 2.
Balb/c mice were infected subcutaneously with 105 NcSpain-7
tachyzoites, a dose that does not induce severe clinical signs in
non-pregnant mice,43 and after 48 h, daily treatments by gavage
(either 2 mg kg1 or 10 mg kg1 of drugs emulsified in corn oil for
5 days) were initiated. Parasite loads in lungs and brain were
determined by real-time PCR at 21 dpi (Fig. 5). In the placebo
group (infected, but treated with corn oil only), two mice showed
symptoms compatible to neosporosis, such as ruﬄed coat and
body tilting, but they did not have to be euthanized as the clinical
score was below the threshold. In the group treated with com-
plexes 1 at 2 mg kg1 day1, one mouse exhibited a ruﬄed coat
and survived, whereas in the group treated with 10 mg kg1
days1, 2 out of 6 mice had to be euthanized on days 14 and
17 dpi. In the group treated with complex 2, one mouse treated
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Fig. 1 Structures of the investigated dinuclear thiolato-bridged arene ruthenium complexes. Complexes 1–7 are symmetrical cationic dinuclear
trithiolato complexes (one thiolato ligand), 8–13 are ‘‘mixed’’ cationic dinuclear trithiolato complexes (two different thiolato ligands), 14–17 are neutral
dithiolato dinuclear complexes, and 18 is a neutral monothiolato dinuclear complex.
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with 2 mg kg1 exhibited clinical signs and survived until the
end of the experiment, while 3 out of 6 mice did in the group
treated with 10 mg kg1 complex 2 for 5 days. All the remaining
mice survived until 21 dpi. No statistically significant eﬀects of
drug treatments on parasite load could be detected in lungs
and in the CNS in any of the drug treated groups. However, the
higher rate of fatalities in the drug treated groups compared to
the placebo group indicates that adverse side eﬀects could play
a role (Fig. 5).
Due to the low IC50 of complex 9 (1  0.3 nM), this
compound was also evaluated in vivo in 2 independent experi-
ments (Fig. 6). First, mice were treated with 2 mg kg1, and
in a second experiment with 10 mg kg1 for 5 days. In
placebo groups (infected, but treated with corn oil only), one
mouse each showed symptoms compatible to neosporosis, but
they did not have to be euthanized. None of the mice in the
group treated with 2 mg kg1, and one of the mice treated
with 10 mg kg1, died during this experiment. Determination
of the parasite load in lungs and CNS by real time PCR
revealed that the average parasite levels in the two organs
of drug treated mice were lower compared to the placebo
group. However, these values were not statistically significant
(Fig. 6). Overall, the ruthenium complexes developed herein
exhibited only limited in vivo eﬃcacy in the neosporosis
mouse model.
Biodistribution of ruthenium complex 1 indicates low drug
levels in the CNS
Since in vivo studies in mice consistently resulted in high level
brain infection comparable to the placebo treatments, we
performed a biodistribution study. ICP-MS biodistribution
analysis was performed in mice that had received a single dose
of 10 mg kg1 of complex 1 by oral gavage. Ruthenium was
identified in blood, liver, kidney and lungs at levels above those
detected for a placebo-treated mouse, demonstrating the drug
absorption after oral administration (Fig. 7). The majority of
the ruthenium was detected in the liver at 3 h and in the kidney
at 48 h post-administration, but no drug was detected in the
brain. These results are in agreement with those previously
reported for complex 2 (also known as diruthenium-1 or DiRu-1)
which had been intraperitoneally injected into mice.26
Discussion
The plethora of compounds that have been developed against
cancer has paved the way for numerous new and innovative
approaches to combat parasitic diseases that aﬀect not only
humans, but also animals. There has been much recent interest
in the development of therapeutic transition metal-based com-
plexes in part fuelled by the clinical success of the platinum(II)
Fig. 2 Total uptake (A) and relative cellular biodistribution (B) of ruthenium in A2780 ovarian carcinoma cells treated for 4 h with 1 mM complex 1, 2 and 5.
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anticancer drug, cisplatin. Yet, known platinum drugs are
limited by their high toxicity, severe side-eﬀects, and incidences
of drug resistance. Organometallic ruthenium-arene complexes
have risen to prominence as a pharmacophore due to the success
of other ruthenium drug candidates in clinical trials.51 Substantial
activities of arene ruthenium complexes have been reported in
infectious diseases caused by bacteria52,53 against protozoan para-
sites including T. gondii29,30 and Plasmodium falciparum,54,55 and
against helminths such as Schistosoma mansoni56,57 and
Echinococcus multilocularis.28 In addition, a series of ruthe-
nium–clotrimazole (ctz) complexes displayed high and specific
in vitro activity against Leishmania major and Trypanosoma
cruzi.58 Other metal complexes containing Ag, Pt, Pd and Au,
already in the market for cancer therapy, treatments of bacterial
infections or as anti-inflammatory agents, have been proposed
for the treatment of trypanosomatid-induced infections.10
A recent review by Gasser et al. provides an overview of metal
complexes against tropical neglected diseases.59
We here report on the in vitro and in vivo activities of 18
dinuclear thiolato-bridged arene ruthenium complexes against
the apicomplexan parasite N. caninum. N. caninum causes
substantial losses in the bovine dairy and meat industry, and
no vaccine and no drugs are currently on the market to limit
these losses.31 Of the 18 complexes investigated herein, three
were identified that exhibited IC50 values between 1 and 62 nM
against N. caninum tachyzoites, and IC50 values between 30
and 530 nM against the ovarian cancer cell line A2780.21–23,41
The mono- and dithiolato complexes 13–18 had been also found
to be only moderately cytotoxic in vitro against cancer cell lines
(IC50 values between 0.2 and 2.5 mM),
25,60,61 reflecting their
propensity to readily hydrolyse and their reactivity towards
biomolecules compared to their trithiolato counterparts.25,45
As indicated in Table 1 for the ovarian carcinoma cell line
A2780, the activity of the complexes against N. caninum largely
mirrors the findings obtained earlier in several cancer cells,21–23,41
and in the closely related apicomplexan parasite Toxoplasma
gondii.30 Generally, the in vitro activity of anticancer and anti-
parasitic drugs can be related in part to their lipophilic character.
The resulting hydrophobicity may contribute to an increased
uptake of the compound by the cells or the parasites, thereby
enhancing the antiproliferative activity. We have previously
evidenced a correlation between lipophilicity and cytotoxic activity
for these types of dinuclear arene ruthenium complexes.21–23,25
Complexes with logP parameters up to the value 4 show a steady
decrease of their IC50 values, which increase again for very
lipophilic complexes with logP values above 4.5, the tendency
being the same for all cell lines investigated.21–23,25 The optimum
lipophilicity for these complexes was found to be for logP values in
Fig. 4 TEM of N. caninum infected HFF cultures treated with complex 9
for 6 h (A), 24 h (B) and 72 h (C and D). Encircled areas mark the
mitochondrion or residues thereof. The designation h-mito indicates the
presence of structurally intact host cell mitochondria associated with
the paraitophorous vacuole membrane; nuc = nucleus, dg = dense
granules, rop = rhoptries. Arrows in C point towards lamellar membrane
stacks. Bars = 1 mM.
Fig. 3 TEM of non-treated N. caninum infected control HFF cultures
(A and B) and cultures exposed to complex 1 (B) and complex 2 (C) for
6 h. The framed area in B is enlarged in A. N. caninum tachyzoites are
located within a parasitophorous vacuole, and the secretory organelles
such as micronemes (mic), rhoptries (rop) and dense granules (dg) are
clearly visible. Mitochondria are encircled, and primary signs of mitochondrial
distortion such as loss of the electron dense matrix are evident already at
6 hours of drug exposure (C and D); nuc = nucleus. Bar = 0.5 mm in A; 2.2 mm
in B; 1.8 mm in C; 1.2 mm in D.
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the range between 3.5 and 4.0, whereas complexes with logP
values lower than 3.5 systematically exhibited a steady increase
of their IC50 values, presumably due to an insufficient cellular
uptake, since the less lipophilic compounds have more difficulties
to cross cell membranes or are more rapidly excreted by exocytosis.
A similar tendency can be found in this study against
N. caninum and previously against T. gondii.30 Complexes with
log P values in the range between 3.0 and 4.0 (1, 2 and 9)
showed the highest cytotoxicities, whereas complexes with log P
values lower than 3.0 (3–8 and 10–13) belong to the less active
ones of the series. If the Hammett constants sP are included,
our results obtained on cancer cells show that the complexes
having Hammett constants in the range 0.2 o sP o 0 and
log P values above 3.0 have the lowest IC50 values.
21–23,25
This tendency seems to be also valid against N. caninum and
T. gondii, as shown in Table 1.
In both cancer cells and the apicomplexan parasite
N. caninum, the mitochondrion represents the major target.
This was shown by ICP-MS in drug treated A2870 cells and by
performing TEM of drug-treated infected HFF. The disruption
of mitochondria has been investigated as a potential novel
chemotherapeutic mechanism for cancer treatment, because it
circumvents upstream apoptotic pathways that may be mutated
or lacking in cancer cells.62 Moreover, cancer cells have higher
mitochondrial membrane potentials, rendering them more
susceptible to mitochondrial perturbations than non-immortalized
cells.63 On the basis of these factors, numerous mitochondria-
targeting agents have been developed in order to disrupt the
Fig. 6 Box plots of parasite loads (no of tachyzoites/mg DNA) in complex
9 treated N. caninum infected Balb/c mice. The drug was applied by oral
gavage of either 2 mg kg1 bodyweight for 5 days (A) or 10 mg kg1
bodyweight during 5 days. Placebo groups received corn oil only.
Fig. 5 Eﬃcacy of complexes 1 and 2 in N. caninum infected Balb/c mice,
treated with oral gavage of either 2 mg kg1 bodyweight for 5 days (A) or
10 mg kg1 bodyweight during 5 days. Placebo groups received corn oil
only. Parasite load in brain and lungs is shown as box plots (no. of
tachyzoites/mg DNA).
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mitochondrial membrane potential and further permeabilise
the mitochondrial outer membrane. It has been reported that
some ruthenium(II) complexes can induce mitochondria –
mediated apoptosis in cancer cells.64
In N. caninum, ICP-MS could not be carried out due to the
lack of protocols for obtaining pure mitochondrial fractions,
but TEM clearly indicated that treatments with ruthenium
complexes 1, 2 and 9 are characterized by severe ultrastructural
alterations in the mitochondrial matrix and cristae early on,
indicating that also in these cells the mitochondrion is the
primary target. Compounds that aﬀect the mitochondrial integrity
in apicomplexan parasites have been identified earlier. For
instance, low nanomolar concentrations of the naphtoquinone
buparvaquone inhibited N. caninum proliferation in vitro at con-
centrations similar to ruthenium complexes, and buparvaquone
also impaired vertical transmission in the pregnant neosporosis
mouse model, but did not aﬀect CNS infection in dams.13 Another
interesting class are endochin-like quinolones (ELQs), which target
the cytochrome bc1 complex of the mitochondrial electron trans-
port chain in protozoan parasites.65 Cytochrome bc1 facilitates the
transfer of electrons from ubiquinol to cytochrome c and contains
both oxidative (Qo) sites and reductive (Qi) catalytic sites. The
anti-malarial drug atovaquone, also used for the treatment
of toxoplasmosis, and buparvaquone, are classical Qo site
inhibitors.66 More recently, novel endochin analogues with a
diphenylether side chain at the third position, and various sub-
stitutions at position 5, 6 or 7 of the quinolone-ring were
synthesized.67,68 One of these compounds, ELQ-400,69 targets both
Qo and Qi sites of cytochrome bc1 of S. cerevisiae and potentially
other organisms.70 ELQ-400 was one of the compounds of out-
standing activity against N. caninum (IC50 2 nM) that was identified
during a screening of the open-source MMV (Medicines for
Malaria Venture) Pathogen Box.71 One of the ELQs with excellent
eﬃcacy against T. gondii is ELQ-316,65 exhibiting in vitro IC50
values below 1 nM, and in vivo aﬀecting not only tachyzoites,
but also tissue cysts.67
In vivo studies on complexes 1, 2 and 9 were carried out using a
standardized non-pregnant Balb/c mouse model for the assessment
of acute and cerebral N. caninum infection. In this model, mice
normally experience mild to medium clinical signs during the acute
phase of infection (day 1–10 post infection), then immunity takes
over and parasites are largely controlled, with the exception of the
brain, which is an immune-privileged site.43,72 This is reflected by
the fact that the parasite load in the lung tissues is clearly lower
compared to the brain in all experiments. For all three complexes,
the results indicated that they did not significantly impact on the
parasite load, neither in the lungs nor in the brain. In addition,
several mice from the treated groups had to be euthanized during
prior to termination of the experiment on day 21 p.i.
A possible explanation for the observed failure of these
complexes to exert activity in mice could be found, as exemplified
for complex 1 in this study, in the respective biodistribution
pattern after oral gavage, which was investigated by ICP-MS,
showing that this compound is well absorbed and detectable
in whole blood after 3 h, but eliminated from blood after 48 h.
Instead, ruthenium was detected in the liver, lungs and kidneys
after 48 h, but at no point in the brain tissue. Similar findings
were obtained earlier when complex 2was injected intraperitoneally
into mice.26 These findings are important as they suggest that
these compounds may be ineﬀective against cerebral parasitic
stages found in cyst-forming coccidia such as Neospora and
Toxoplasma.
Conclusion
In conclusion, this study demonstrated that dinuclear thiolato-
bridged arene ruthenium complexes target the mitochondrion
in cancer cells as well as in the proliferative stages of apicomplexan
parasites such as N. caninum. For future development of this class of
compounds, it will be of interest to investigate which parts of the
mitochondria (i.e. DNA, membrane, etc.), or potentially also other
targets mediate the eﬃcacy. The lipophilicity as well as the ligands
undoubtedly play an important role for future design of dinuclear
thiolato-bridged arene ruthenium complexes and conjugates. Addi-
tional studies, including a broader panel of parasites, as well as new
dinuclear thiolato-bridged arene ruthenium conjugates bearing
known anti-parasitic drugs such as atovaquone and buparvaquone,
are needed to define precisely the antiparasitic eﬀectiveness and
potential of these ruthenium complexes as well as their molecular
targets andmodes of action. Overall, our work opens new avenues in
the field of parasitology, as it clearly demonstrates, using metallo-
mics studies, the importance of targeting mitochondria in parasites.
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